|Bid||103.94 x 1000|
|Ask||103.75 x 1200|
|Day's Range||103.09 - 105.39|
|52 Week Range||82.12 - 121.98|
|Beta (3Y Monthly)||1.52|
|PE Ratio (TTM)||43.64|
|Earnings Date||Oct 29, 2019 - Nov 4, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||112.55|
Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of...
A Raleigh-based clinical research organization plans a stock buyback worth half a billion dollars as its largest institutional shareholder plans to sell its stake.
PRA Health Sciences, Inc. (the “Company”) (PRAH) today announced the pricing of the previously announced secondary offering of shares of its common stock. KKR PRA Investors L.P. (the “Selling Stockholder”), has agreed to sell an aggregate of 6,666,684 shares of the Company’s common stock in an underwritten public offering at a price of $97.50 per share. In addition, the Company announced that, subject to the completion of the offering, it intends to repurchase from the underwriter, out of 6,666,684 shares of common stock, a number of shares having an aggregate purchase price of $300 million at a price per share equal to the price at which the underwriter will purchase the shares from the Selling Stockholder. The Company intends to fund the repurchase of common stock from the Selling Stockholder with the proceeds of a $300 million incremental term loan under its existing credit facilities.
Under the program, the Company is authorized to repurchase shares of its common stock through open market purchases, privately-negotiated transactions, secondary offerings, block trades or otherwise in accordance with all applicable securities laws and regulations, including through trading plans complying with the rules and regulations of the Securities and Exchange Commission (the “SEC”). In addition, the Company announced that, subject to the completion of the announced underwritten secondary offering of the Company’s common stock by KKR PRA Investors L.P. (the “Selling Stockholder”), it intends to repurchase from the underwriter in such offering, out of the 6,666,684 shares of common stock, a number of shares having an aggregate purchase price of $300 million at a price per share equal to the price at which the underwriter will purchase the shares from the Selling Stockholder.
PRA Health Sciences, Inc. (the “Company”) (PRAH) today announced that KKR PRA Investors L.P. (the “Selling Stockholder”), intends to offer for sale in an underwritten secondary offering 6,666,684 shares of common stock of the Company pursuant to the Company’s shelf registration statement filed with the Securities and Exchange Commission. No shares are being sold by the Company. The last reported sale price of the Company’s common stock on September 3, 2019 was $97.59 per share.
Medical technology companies are rising bullishly in 2019. The best-performing medical stocks tend to have high Composite Ratings, reflecting strong growth metrics vs. all other stocks.
PRA Health Sciences (PRAH) announced today that Symphony Health, the company’s data solutions division, has expanded its global data services by entering into a strategic partnership with Close-Up International, a leading Latin American-based provider of medical prescription and sales audits. “The agreement with Close-Up represents a significant milestone in Symphony Health’s commitment to expanding our services internationally,” said Doug Fulling, President of Symphony Health. “The presence across up to a dozen geographies adds a critical component to Symphony’s offerings that will build and strengthen relationships for both organizations in the United States and Latin America.
A Triangle-based contract research organization says Asian-Pacific markets present a massive opportunity for expansion, potentially adding to its already double-digit growth.
PRA Health Sciences (PRAH) delivered earnings and revenue surprises of 1.67% and -0.11%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Net new business of $670.7 million; Net book-to-bill of 1.24$763.3 million of total revenue; representing 5.6% growth at actual foreign exchange rates and 6.8% growth on a.
PRA Health Sciences (PRAH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In a release issued under the same headline on July 9, 2019 by PRA Health Sciences, Inc. (PRAH), please note that in the second paragraph of the release, the conference call ID and replay ID should read "6295812" and not "1876878" as previously stated. PRA Health Sciences, Inc. (NASDAQ: PRAH) will release its second quarter 2019 results after the market closes on Wednesday, July 31, 2019. The Company will also host a conference call on Thursday, August 1, 2019 at 9:00 a.m. (ET) to discuss the results with members of the investment community.
RALEIGH, N.C., July 09, 2019 -- PRA Health Sciences, Inc. (NASDAQ: PRAH) will release its second quarter 2019 results after the market closes on Wednesday, July 31, 2019. The.
It hasn't been the best quarter for PRA Health Sciences, Inc. (NASDAQ:PRAH) shareholders, since the share price has...
It is already common knowledge that individual investors do not usually have the necessary resources and abilities to properly research an investment opportunity. As a result, most investors pick their illusory “winners” by making a superficial analysis and research that leads to poor performance on aggregate. Since stock returns aren't usually symmetrically distributed and index […]
PRA Health (PRAH) is gaining steadily from expansion in international markets, solid 2019 outlook and growing CRO industry. However, tough capital spending environment remains a woe.
PRA Health Sciences Inc NASDAQ/NGS:PRAHView full report here! Summary * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for PRAH with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting PRAH. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding PRAH totaled $150 million. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
PRA Health Sciences (PRAH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
PRA Health Sciences, Inc. is pleased to announce it has received an array of awards and recognition during the first months of 2019. This is the seventh consecutive year that the company has won this prestigious industry award. Clinical Researcher of the Year – The Americas is a real-world competition that recognizes the talent and passion of industry and academic researchers and is considered a key barometer of quality standards in the clinical research organization (CRO) industry.